• Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Epidermolysis Bullosa (EB) Therapeutics - Pipeline Analysis 2018. Show all posts
Showing posts with label Epidermolysis Bullosa (EB) Therapeutics - Pipeline Analysis 2018. Show all posts

Epidermolysis Bullosa (EB) Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations


Epidermolysis bullosa (EB), is a rare genetic connective tissue skin disorder that causes blisters and allows skin to become fragile. Blisters and areas of skin loss (erosions) occur in response to minor injury or friction, such as rubbing or scratching. The disease affects 1 out of every 20,000 births in the U.S. The symptoms of epidermolysis bullosa are redness and heat around an open area of skin; crusting on the wound surface; pus or yellow fluid discharge; red line or streak under the skin that spreads away from the blistered area; wound; and fever or chills.


Request to Get the Sample Pages at: 

Epidermolysis bullosa can be diagnosed through skin biopsy, prenatal and genetic testing. In order to treat the disease, surgical treatment or rehabilitation therapy can be opted. It can also be managed by daily wound care, pain management, and protective bandaging.

Access Detailed Report Summary:

The drug candidates of epidermolysis bullosa pipeline include, but not limited to, EB 101, FCX 007, and Diacerein. Some of the companies having drugs in the epidermolysis bullosa therapeutics pipeline includes Abeona Therapeutics Inc., TWi Pharmaceuticals Inc. and Fibrocell Science Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Share:

Profile

Popular Posts

APSense

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages